These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 2113103)

  • 1. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding.
    Edelson JT; Tosteson AN; Sax P
    JAMA; 1990 Jul; 264(1):41-7. PubMed ID: 2113103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of prophylactic treatment with Misoprostol in osteoarthritic patients treated with NSAIDs. The case of Belgium.
    Carrin GJ; Torfs KE
    Rev Epidemiol Sante Publique; 1990; 38(3):187-99. PubMed ID: 2118670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness of preventive treatment with misoprostol in non-steroidal anti-inflammatory agents related gastric ulcers].
    de Pouvourville G; Bader JP
    Gastroenterol Clin Biol; 1991; 15(5):399-404. PubMed ID: 1906413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications.
    Koch M; Dezi A; Tarquini M; Capurso L
    Dig Liver Dis; 2000 Mar; 32(2):138-51. PubMed ID: 10975790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions.
    Davis R; Yarker YE; Goa KL
    Drugs Aging; 1995 Nov; 7(5):372-93. PubMed ID: 8573992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to evaluate drugs. Cost-effectiveness analysis.
    Beck JR
    JAMA; 1990 Jul; 264(1):83-4. PubMed ID: 2113106
    [No Abstract]   [Full Text] [Related]  

  • 8. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
    Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost effectiveness of misoprostol prophylaxis alongside long-term nonsteroidal anti-inflammatory drugs. Implications of the MUCOSA trial.
    Davey PJ; Meyer E
    Pharmacoeconomics; 2000 Mar; 17(3):295-304. PubMed ID: 10947304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug- and aspirin-associated ulcer bleeding: a cross-sectional study.
    Ho CW; Tse YK; Wu B; Mulder CJ; Chan FK
    Aliment Pharmacol Ther; 2013 Apr; 37(8):819-24. PubMed ID: 23432193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing upper gastrointestinal bleeding in patients receiving nonsteroidal antiinflammatory drugs.
    Elliott DP
    DICP; 1990 Oct; 24(10):954-8. PubMed ID: 2123049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials.
    Koch M; Dezi A; Ferrario F; Capurso I
    Arch Intern Med; 1996 Nov; 156(20):2321-32. PubMed ID: 8911239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis.
    El-Serag HB; Graham DY; Richardson P; Inadomi JM
    Arch Intern Med; 2002 Oct; 162(18):2105-10. PubMed ID: 12374519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs.
    Hillman AL; Bloom BS
    Arch Intern Med; 1989 Sep; 149(9):2061-5. PubMed ID: 2505706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
    de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
    Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs.
    Gabriel SE; Campion ME; O'Fallon WM
    Arthritis Rheum; 1994 Mar; 37(3):333-41. PubMed ID: 8129789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Misoprostol and ulcer prophylaxis.
    Upadhyay R; Taha AS; Sturrock RD; Russell RI
    Lancet; 1989 Jan; 1(8631):212-3. PubMed ID: 2563111
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advances in defining the role of misoprostol in rheumatology.
    Nicholson PA
    J Rheumatol Suppl; 1990 Feb; 20():50-3. PubMed ID: 2109076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis?
    Goldstein JL
    Eur J Gastroenterol Hepatol; 2000 Jun; 12 Suppl 1():S11-5. PubMed ID: 10929893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.
    Barradell LB; Whittington R; Benfield P
    Pharmacoeconomics; 1993 Feb; 3(2):140-71. PubMed ID: 10146962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.